Lantheus (LNTH) Stock Price, News & Analysis

Company Overview

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology.

The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures. Lantheus also offers other imaging agents, including products used in brain imaging.

Founded in 1956, Lantheus serves healthcare providers in the United States and internationally. Its business includes established imaging products as well as the development of new radiopharmaceuticals for disease detection and treatment.

Key Stats

• Today's Range: $101.39 to $101.70
• 50-Day Range: $99.51 to $101.62
• 52-Week Range: $51.47 to $111.86
• Volume: 1.02 million shs
• Average Volume: 1.09 million shs
• Market Capitalization: $6.64 billion
• P/E Ratio: 25.02
• Dividend Yield: N/A
• Price Target: $107.44
• Consensus Rating: Hold

Lantheus Stock Analysis - MarketRank™

Lantheus scored higher than 54% of companies evaluated by MarketBeat, and ranked 429th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Lantheus has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on no strong buy ratings, 3 buy ratings, 11 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Lantheus is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Lantheus has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 23.57%

Earnings Growth

Earnings for Lantheus are expected to grow by 23.57% in the coming year, from $4.54 to $5.61 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lantheus is 25.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lantheus is 25.02, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.12.

Price to Book Value per Share Ratio

Lantheus has a P/B Ratio of 4.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.67% of the float of Lantheus has been sold short.

Short Interest Ratio / Days to Cover

Lantheus has a short interest ratio ("days to cover") of 3.23, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lantheus has recently increased by 0.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lantheus does not currently pay a dividend.

Dividend Growth

Lantheus does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.62

News Sentiment

Lantheus has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Lantheus this week, compared to 4 articles on an average week.

MarketBeat Follows

3 people have added Lantheus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lantheus insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of Lantheus is held by insiders.

Percentage Held by Institutions

99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LNTH
• CIK: 1521036
• Web: www.lantheus.com
• Phone: (978) 671-8001
• Fax: 978-671-8860
• Employees: 1,193
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lantheus: $107.44
• High Price Target: $129.00
• Low Price Target: $94.00
• Potential Upside/Downside: +5.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.21
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.06
• Trailing P/E Ratio: 25.02
• Forward P/E Ratio: 18.11
• P/E Growth: N/A
• Net Income: $233.56 million
• Net Margins: 17.28%
• Pretax Margin: 21.92%
• Return on Equity: 29.26%
• Return on Assets: 15.40%

Debt

• Debt-to-Equity Ratio: 0.42
• Current Ratio: 3.25
• Quick Ratio: 3.06

Sales & Book Value

• Annual Sales: $1.54 billion
• Price / Sales: 4.31
• Cash Flow: $6.39 per share
• Price / Cash Flow: 15.91
• Book Value: $20.73 per share
• Price / Book: 4.90

Miscellaneous

• Outstanding Shares: 65,400,000
• Free Float: 64,289,000
• Market Cap: $6.64 billion
• Optionable: Optionable
• Beta: 0.01